The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of total androgen blockade, weekly docetaxel, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.
Stephen J. Ramey
No relevant relationships to disclose
Ali Reza Golshayan
No relevant relationships to disclose
Thomas E. Keane
No relevant relationships to disclose
Andrew S. Kraft
No relevant relationships to disclose
Uzair Bashir Chaudhary
No relevant relationships to disclose
David T. Marshall
No relevant relationships to disclose